Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 3/20 | 0.61 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2189865 | 0.90 | PIK3CA (0.82) | PIK3CAABCG2ABCB1HTR2CBCDIN3D | |
| SCHEMBL2190241 | 0.85 | PIK3CA (1.00) | PIK3CAHTR2CBCDIN3D | |
| SCHEMBL2191671 | 0.84 | PIK3CA (0.84) | PIK3CAHTR2CBCDIN3D | |
| SCHEMBL2192316 | 0.84 | PIK3CA (0.79) | PIK3CAABCG2HTR2CBCDIN3D | |
| SCHEMBL24532060 | 0.84 | MAPK14 (0.77) | PIK3CAABCG2ABCB1 | |
| SCHEMBL2193924 | 0.82 | PIK3CA (0.76) | PIK3CAABCG2ABCB1HTR2C | |
| SCHEMBL2191664 | 0.81 | PIK3CA (0.69) | PIK3CAABCG2ABCB1HTR2C | |
| SCHEMBL2191648 | 0.80 | PIK3CA (0.75) | PIK3CAHTR2CBCDIN3D | |
| SCHEMBL2194956 | 0.80 | PIK3CA (0.73) | PIK3CAABCG2HTR2CBCDIN3D | |
| SCHEMBL2193191 | 0.80 | PIK3CA (0.72) | PIK3CAHTR2CBCDIN3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252616-B1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-07-23 | — | — | EP | claimed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | claimed |
| EP-2252616-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2010-11-24 | — | — | EP | claimed |
| WO-2009097446-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-08-06 | — | — | WO | claimed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2252616-B1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2252616-B1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| EP-2252616-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009097446-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172216-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | PIK3CA 1/4885ABCG2 966/4885ABCB1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.